San Diego-primarily based Viking Therapeutics marked alone as a serious competitor during the weight loss drug market place in February just after revealing promising knowledge from a mid-phase trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when given for a weekly injection and in March the co